Chief Development Officer · KalVista Pharmaceuticals, Inc. (KALV)

Christopher Yea

A named executive officer of KalVista Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,650,617

Salary $477,750Stock awards $871,479Bonus $133,770

FY2022: $2,676,955

3rd of 3 named executive officers at KalVista Pharmaceuticals by FY2023 total.

3 named officers on file for KalVista Pharmaceuticals, FY2023

Christopher Yea’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how KalVista Pharmaceuticals’s whole pay program stands against its peers

  • KalVista Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KALV→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed August 22, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Christopher Yea’s full pay file as a PDF — free

More than this page: up to 10 years of Christopher’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Christopher Yea compensation by year

KalVista Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as KalVista Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$455,000$477,750
Bonus$182,000$133,770
Stock awards$923,400$871,479
Option awards$1,089,276$138,909
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$27,279$28,709
Total$2,676,955$1,650,617

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: KalVista Pharmaceuticals, Inc. DEF 14A filed August 22, 2024, accession 0001193125-24-205356, and prior-year filings.

How this page was built: the KalVista Pharmaceuticals, Inc. filed document, accession 0001193125-24-205356. Every figure is read from that document and cited to the page and table it appears in. Filed August 22, 2024.

$2.7M
$1.7M
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU60,000$409,200—
PSU21,875$278,031—
RSU15,964$148,146—
RSU17,014$116,035—
PSU7,292$72,847—
Option13,334—$10.20
Option16,250—$25.95
Option9,855—$9.28

Per the Outstanding Equity Awards at Fiscal Year-End table in KalVista Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

72 Form 4 lines since the FY2023 proxy (filed August 22, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-11Disposition to the issuer—229,918$0.000
2026-06-11Disposition to the issuer derivative—52,600—0
2026-06-11Disposition to the issuer derivative—31,000—0
2026-06-11Disposition to the issuer derivative—25,000—0
2026-06-11Disposition to the issuer derivative—53,500—0
2026-06-11Disposition to the issuer derivative—80,000—0
2026-06-11Disposition to the issuer derivative—60,000—0
2026-06-11Disposition to the issuer derivative—27,900—0

The 8 most recent of 72 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

KalVista Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
T. Andrew CrockettFormer Chief Executive Officer$3,634,983
Benjamin PalleikoChief Executive Officer$2,420,747
Christopher Yea · this pageChief Development Officer$1,650,617

The full KalVista Pharmaceuticals compensation record

free company brief

This page is one person within KalVista Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are KalVista Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christopher Yea's compensation dossier · One-time report. No refunds.